2021
DOI: 10.1016/j.jconrel.2021.02.027
|View full text |Cite
|
Sign up to set email alerts
|

Semi-solid extrusion 3D printing in drug delivery and biomedicine: Personalised solutions for healthcare challenges

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
91
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
5
5

Relationship

2
8

Authors

Journals

citations
Cited by 201 publications
(106 citation statements)
references
References 162 publications
0
91
0
Order By: Relevance
“…Fused deposition modelling (FDM) and Semi Solid Extrusion (SSE) are the most straightforward technologies to prepare different mixtures and combinations Pharmaceutics 2021, 13, 907 2 of 16 of drugs and excipients, where the active pharmaceutical ingredient (API) is directly blended with or impregnated in the excipient/carrier to subsequently be processed. Seoane-Viaño et al [18] did a thorough review of SSE, highlighting the numerous applications this technology has and discussing some of its drawbacks: post-printing drying process, complete solvent evaporation, risk of material collapse and loss of shape. On the contrary, FDM does not show those post processing problems, but it is limited by the low number of Food and Drug Administration (FDA) approved thermoplastic polymers and the thermal degradation the drug undergoes during the process [14,19,20].…”
Section: Introductionmentioning
confidence: 99%
“…Fused deposition modelling (FDM) and Semi Solid Extrusion (SSE) are the most straightforward technologies to prepare different mixtures and combinations Pharmaceutics 2021, 13, 907 2 of 16 of drugs and excipients, where the active pharmaceutical ingredient (API) is directly blended with or impregnated in the excipient/carrier to subsequently be processed. Seoane-Viaño et al [18] did a thorough review of SSE, highlighting the numerous applications this technology has and discussing some of its drawbacks: post-printing drying process, complete solvent evaporation, risk of material collapse and loss of shape. On the contrary, FDM does not show those post processing problems, but it is limited by the low number of Food and Drug Administration (FDA) approved thermoplastic polymers and the thermal degradation the drug undergoes during the process [14,19,20].…”
Section: Introductionmentioning
confidence: 99%
“…Special patient populations were actively acknowledged in the movement, exemplified by the case of 3DP tablets incorporating Braille designs for the visually impaired [37,38]. Bioprinting, a branch of 3DP capable of printing living cells, was also conceived, promising a future of 3DP organs and probiotic therapies [39][40][41][42]. Despite encouraging results when tested in vitro and in vivo using animal models of disease, few 3DP pharmaceuticals have entered human studies and none has followed in the footsteps of Spritam® with market approval.…”
Section: Moving 3dp Of Pharmaceuticals Beyond the Laboratory And Into The Clinicmentioning
confidence: 99%
“…Generally, an incredible advantage of 3D printing is the possibility of the fabrication of complex structures, unprofitable to manufacture using injection molding methods [5]. Furthermore, 3D printers have been improved for extremely high resolution, which fosters their use in tissue engineering.…”
Section: Introductionmentioning
confidence: 99%